Parker Scott 2/20/25 Parker Scott 2/20/25 PolarityBio Receives U.S. FDA Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers (DFU) Read More Guest User 12/3/24 Guest User 12/3/24 PolarityBio Announces Interim Enrollment Achieved in SkinTE’s Phase III Pivotal Study Read More Guest User 5/20/24 Guest User 5/20/24 PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers Read More Guest User 2/26/24 Guest User 2/26/24 PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers Read More
Parker Scott 2/20/25 Parker Scott 2/20/25 PolarityBio Receives U.S. FDA Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers (DFU) Read More
Guest User 12/3/24 Guest User 12/3/24 PolarityBio Announces Interim Enrollment Achieved in SkinTE’s Phase III Pivotal Study Read More
Guest User 5/20/24 Guest User 5/20/24 PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers Read More
Guest User 2/26/24 Guest User 2/26/24 PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers Read More
